Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2009 Jan;9(1):71-8. doi: 10.1517/14712590802614538 .

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).

Author information

1
University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX 77030, USA. eamitten@mdanderson.org

Abstract

BACKGROUND:

Early clinical trials of HER2/neu-derived peptide vaccines indicate that they may be useful for preventing recurrence in breast cancer patients rendered disease-free after standard-of-care therapy. An effective vaccination strategy will probably require stimulation of T helper (Th) cells. AE37 is an HER2/neu-derived peptide that has been modified to enhance antigen-specific stimulation of Th cells by linkage of the Ii-Key moiety of the MHC class II-associated invariant chain (Ii protein).

OBJECTIVE:

To review the literature regarding the role of a Th response in immunotherapy with a focus on this novel HER2/neu-derived AE37 peptide.

RESULTS/CONCLUSION:

Improved immuno-genicity of the AE37 Ii-key hybrid peptide has been demonstrated in animal models, ex vivo patient cells, and, most recently, in a Phase I clinical trial in breast cancer patients. Future clinical trials incorporating AE37 into a peptide vaccine strategy are warranted.

PMID:
19063694
DOI:
10.1517/14712590802614538
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center